Generic maker pays $145m to settle antitrust suit
21-07-2022
Endo pays $2.3m to settle states antitrust claims
22-07-2019
Endo resolves FTC allegations over Lidoderm and Opana ER
24-01-2017
OleksandrShnuryk / Shutterstock.com
Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Endo, Amneal, Impax, antitrust, generic, class action lawsuit
